Targeting the Gatekeeper MET146 of C-Jun N-Terminal Kinase 3 Induces a Bivalent Halogen/Chalcogen Bond.

We target the gatekeeper MET146 of c-Jun N-terminal kinase 3 (JNK3) to exemplify the applicability of X···S halogen bonds in molecular design using computational, synthetic, structural and biophysical techniques. In a designed series of aminopyrimidine-based inhibitors, we unexpectedly encounter a plateau of affinity. Compared to their QM-calculated interaction energies, particularly bromine and iodine fail to reach the full potential according to the size of their σ-hole. Instead, mutation of the gatekeeper residue into leucine, alanine, or threonine reveals that the heavier halides can significantly influence selectivity in the human kinome. Thus, we demonstrate that, although the choice of halogen may not always increase affinity, it can still be relevant for inducing selectivity. Determining the crystal structure of the iodine derivative in complex with JNK3 (4X21) reveals an unusual bivalent halogen/chalcogen bond donated by the ligand and the back-pocket residue MET115. Incipient repulsion from the too short halogen bond increases the flexibility of Cε of MET146, whereas the rest of the residue fails to adapt being fixed by the chalcogen bond. This effect can be useful to induce selectivity, as the necessary combination of methionine residues only occurs in 9.3% of human kinases, while methionine is the predominant gatekeeper (39%).

[1]  P. Caron,et al.  Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. , 1998, Structure.

[2]  O. Ottoni,et al.  EFFICIENT AND SIMPLE METHODS FOR THE INTRODUCTION OF THE SULFONYL, ACYL AND ALKYL PROTECTING GROUPS ON THE NITROGEN OF INDOLE AND ITS DERIVATIVES , 1998 .

[3]  Martin Lepšík,et al.  Quantum mechanical scoring: structural and energetic insights into cyclin-dependent kinase 2 inhibition by pyrazolo[1,5-a]pyrimidines. , 2013, Current computer-aided drug design.

[4]  Thomas E. Exner,et al.  Data quality in drug discovery: the role of analytical performance in ligand binding assays , 2015, Journal of Computer-Aided Molecular Design.

[5]  Pierangelo Metrangolo,et al.  Definition of the halogen bond (IUPAC Recommendations 2013) , 2013 .

[6]  Markus O. Zimmermann,et al.  Using halogen bonds to address the protein backbone: a systematic evaluation , 2012, Journal of Computer-Aided Molecular Design.

[7]  Anton Simeonov,et al.  Fluorescence polarization assays in small molecule screening , 2011, Expert opinion on drug discovery.

[8]  S. Laufer,et al.  c-Jun N-terminal kinase inhibitors: a patent review (2010 – 2014) , 2015, Expert opinion on therapeutic patents.

[9]  Wolfgang Albrecht,et al.  Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. , 2012, Nature chemical biology.

[10]  Markus O. Zimmermann,et al.  Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53 , 2012, Journal of the American Chemical Society.

[11]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[12]  Yu Zhang,et al.  Chalcogen bond: a sister noncovalent bond to halogen bond. , 2009, The journal of physical chemistry. A.

[13]  Peter Politzer,et al.  An overview of halogen bonding , 2007, Journal of molecular modeling.

[14]  Martin Lepšík,et al.  Modulation of aldose reductase inhibition by halogen bond tuning. , 2013, ACS chemical biology.

[15]  Pierre Koch,et al.  Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. , 2014, Future medicinal chemistry.

[16]  Timothy Clark,et al.  Halogen bonding and other σ-hole interactions: a perspective. , 2013, Physical chemistry chemical physics : PCCP.

[17]  György G. Ferenczy,et al.  Enthalpic Efficiency of Ligand Binding , 2010, J. Chem. Inf. Model..

[18]  A. Joerger,et al.  Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.

[19]  Horst Köppel,et al.  Theoretical investigations on chalcogen-chalcogen interactions: what makes these nonbonded interactions bonding? , 2006, Journal of the American Chemical Society.

[20]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[21]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[22]  B. Beno,et al.  A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. , 2015, Journal of medicinal chemistry.

[23]  Richard J. Marhöfer,et al.  Molecular Graphics - Trends and Perspectives , 2000 .

[24]  François Diederich,et al.  Systematic investigation of halogen bonding in protein-ligand interactions. , 2011, Angewandte Chemie.

[25]  J. Murray,et al.  Simultaneous σ-hole and hydrogen bonding by sulfur- and selenium-containing heterocycles , 2008 .

[26]  T. Ceska,et al.  Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[27]  M. Prudhomme,et al.  Synthesis of aminopyrimidylindoles structurally related to meridianins , 2007 .

[28]  Jindřich Fanfrlík,et al.  Halogen bond tunability I: the effects of aromatic fluorine substitution on the strengths of halogen-bonding interactions involving chlorine, bromine, and iodine , 2011, Journal of molecular modeling.

[29]  Michael S. Cohen,et al.  Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors , 2005, Science.

[30]  Barbara Kirchner,et al.  Addressing Methionine in Molecular Design through Directed Sulfur-Halogen Bonds. , 2011, Journal of chemical theory and computation.

[31]  J. Murray,et al.  σ-hole bonding: molecules containing group VI atoms , 2007 .

[32]  Britt-Marie Swahn,et al.  Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. , 2005, Bioorganic & medicinal chemistry letters.

[33]  Eric Westhof,et al.  Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Lisnock,et al.  The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. , 2003, Chemistry & biology.

[35]  Markus O. Zimmermann,et al.  Targeting Histidine Side Chains in Molecular Design through Nitrogen-Halogen Bonds , 2013, J. Chem. Inf. Model..

[36]  Pierre Koch,et al.  Inhibitors of c-Jun N-terminal kinases: an update. , 2015, Journal of medicinal chemistry.

[37]  Michal Otyepka,et al.  Semiempirical quantum mechanical method PM6-DH2X describes the geometry and energetics of CK2-inhibitor complexes involving halogen bonds well, while the empirical potential fails. , 2011, The journal of physical chemistry. B.

[38]  C. Peifer,et al.  Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase. , 2010, Analytical biochemistry.

[39]  Xueliang Fang,et al.  Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. , 2004, Analytical biochemistry.

[40]  Markus O. Zimmermann,et al.  Evaluating the Potential of Halogen Bonding in Molecular Design: Automated Scaffold Decoration Using the New Scoring Function XBScore , 2015, J. Chem. Inf. Model..

[41]  P. Molina,et al.  Synthesis and cytotoxic evaluation of new derivatives of the marine alkaloid variolin B. , 2006, Journal of medicinal chemistry.